All Stories

  1. SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic
  2. Human MERS-CoV cases are falling but pose an ongoing pandemic threat
  3. Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults
  4. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies
  5. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination
  6. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination
  7. SARS-CoV-2 cross-reactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic
  8. Human organoid models to study coronavirus infections of the respiratory tract
  9. Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies
  10. The role of gowns in preventing nosocomial transmission of respiratory viruses: a systematic review
  11. Long-term culture of chicken tracheal organoids for the purpose of avian influenza virus research
  12. Variable DPP4 expression in multiciliated cells of the human nasal epithelium as a determinant for MERS-CoV tropism
  13. A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies
  14. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
  15. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters
  16. Detection of Double-Stranded RNA Intermediates During SARS-CoV-2 Infections of Syrian Golden Hamsters with Monoclonal Antibodies and Its Implications for Histopathological Evaluation of In Vivo Studies
  17. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
  18. Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression
  19. Advancing COVID-19 diagnostics: rapid detection of intact SARS-CoV-2 using viability RT-PCR assay
  20. Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters
  21. Dissecting humoral immune responses to an MVA-vectored MERS vaccine in humans using a systems serology approach
  22. Virus neutralization assays for human respiratory syncytial virus using airway organoids
  23. Profiling the SARS-CoV-2-specific T-cell response
  24. Nachweis doppelsträngiger RNS-Intermediate bei verschiedenen Varianten des schweren akuten respiratorischen Syndrom-Coronavirus-2 (SARS-CoV-2) in formalinfixiertem, paraffineingebettetem Lungengewebe experimentell infizierter Hamster
  25. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  26. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
  27. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
  28. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution
  29. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
  30. A pan-orthohantavirus preclinical human lung xenograft mouse model
  31. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
  32. Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in in vivo models
  33. Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans
  34. Human conjunctiva organoids to study ocular surface homeostasis and disease
  35. The Safety, Immunogenicity, and Optimal Dosing of an MVA-Based Vaccine Against MERS Coronavirus in Healthy Adults: A Phase 1b, Randomised, Placebo-Controlled, Double-Blind Clinical Trial
  36. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  37. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients
  38. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
  39. Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses
  40. Antigenic evolution of SARS coronavirus 2
  41. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
  42. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
  43. SARS-CoV-2 ORF8 accessory protein is a virulence factor
  44. Distinct COVID-19 vaccine combinations result in divergent immune responses
  45. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface
  46. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
  47. Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models
  48. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
  49. Correction for Mols et al., “Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host”
  50. Detection of double-stranded RNA intermediates of four major SARS-CoV-2 variants in formalin-fixed paraffin-embedded lung tissue of Syrian golden hamsters using monoclonal antibodies
  51. SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
  52. ICTV Virus Taxonomy Profile: Coronaviridae 2023
  53. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  54. Mpox Virus Impact on Kidney Organoids and Antiviral Treatment Response
  55. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica, C1.
  56. Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain
  57. Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat ( Pipistrellus nathusii ), Its Natural Host
  58. Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein
  59. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
  60. Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands
  61. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
  62. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  63. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  64. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  65. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial
  66. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  67. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  68. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids
  69. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
  70. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas
  71. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
  72. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
  73. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
  74. An early warning system for emerging SARS-CoV-2 variants
  75. Review 1: "Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets"
  76. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  77. Methods for fighting emerging pathogens
  78. Defining the risk of SARS-CoV-2 variants on immune protection
  79. SARS-CoV-2 pathogenesis
  80. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  81. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  82. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns
  83. Spreading of SARS-CoV-2 from hamsters to humans
  84. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
  85. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
  86. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  87. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets
  88. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  89. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)
  90. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
  91. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
  92. Middle East respiratory syndrome coronavirus infection in camelids
  93. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
  94. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands
  95. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
  96. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens
  97. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021
  98. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  99. Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  100. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  101. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  102. Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients
  103. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
  104. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
  105. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  106. Interferon-α Auto-Antibodies in Convalescent Plasma Therapy for COVID-19
  107. Science, not speculation, is essential to determine how SARS-CoV-2 reached humans
  108. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
  109. Animal models of SARS-CoV-2 transmission
  110. Advancing lung organoids for COVID-19 research
  111. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
  112. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  113. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  114. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  115. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures
  116. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  117. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
  118. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7
  119. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019
  120. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  121. Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  122. A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
  123. 3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements
  124. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  125. Review for "A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice"
  126. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
  127. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  128. Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients
  129. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  130. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
  131. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
  132. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  133. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  134. Extended Shedding and Enhanced Fitness of the SARS-CoV-2 Variant of Concern B.1.1.7 in Human Organoid Systems
  135. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses
  136. Susceptibility of rabbits to SARS-CoV-2
  137. Author response: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  138. Decision letter: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  139. An Organoid‐derived Bronchioalveolar Model for SARS‐CoV‐2 Infection of Human Alveolar‐type II‐like Cells
  140. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens
  141. Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.
  142. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis
  143. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  144. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
  145. Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques
  146. How the COVID-19 pandemic highlights the necessity of animal research
  147. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
  148. Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
  149. Animal models for COVID-19
  150. The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells
  151. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  152. Susceptibility of rabbits to SARS-CoV-2
  153. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands
  154. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  155. How the COVID-19 pandemic highlights the necessity of animal research
  156. Assessing the extent of SARS-CoV-2 circulation through serological studies
  157. SARS-CoV-2 is transmitted via contact and via the air between ferrets
  158. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
  159. Convalescent Plasma for COVID-19. A randomized clinical trial
  160. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients
  161. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
  162. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  163. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
  164. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
  165. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  166. A human monoclonal antibody blocking SARS-CoV-2 infection
  167. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies
  168. SARS-CoV-2 productively infects human gut enterocytes
  169. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
  170. SARS-CoV-2 Productively Infects Human Gut Enterocytes
  171. Targeted Proteomics for the Detection of SARS-CoV-2 Proteins
  172. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
  173. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
  174. SARS-CoV-2 is transmitted via contact and via the air between ferrets.
  175. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya
  176. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
  177. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  178. SARS-CoV-2 specific antibody responses in COVID-19 patients
  179. Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model
  180. A human monoclonal antibody blocking SARS-CoV-2 infection
  181. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  182. Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
  183. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
  184. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group
  185. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19
  186. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  187. Note from the editors: novel coronavirus (2019-nCoV)
  188. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
  189. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection
  190. MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017
  191. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts
  192. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
  193. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
  194. ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity
  195. Failure to detect MERS‐CoV RNA in urine of naturally infected dromedary camels
  196. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors
  197. Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits
  198. Host Determinants of MERS-CoV Transmission and Pathogenesis
  199. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
  200. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein
  201. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas
  202. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
  203. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4
  204. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
  205. Multi-hospital outbreak of a Middle East respiratory syndrome coronavirus deletion variant, Jordan: A molecular, serologic, and epidemiologic investigation
  206. Tissue Distribution of the Mers-Coronavirus Receptor in Bats
  207. Cell Tropism of Middle East Respiratory Syndrome Coronavirus in Experimentally Infected Dromedaries
  208. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
  209. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients
  210. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells
  211. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
  212. Middle East respiratory syndrome coronavirus experimental transmission using a pig model
  213. MERS-coronavirus: From discovery to intervention
  214. Genetic diversity of hepatitis C virus in Ethiopia
  215. Tissue Distribution of the MERS-Coronavirus Receptor in Bats
  216. Virus genomes reveal factors that spread and sustained the Ebola epidemic
  217. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study
  218. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches
  219. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia
  220. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus
  221. Respiratory Infection Routes of MERS-CoV in Rabbits
  222. Development of Different Animal Models for Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
  223. The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction
  224. A novel hepatitis B virus subgenotype D10 circulating in Ethiopia
  225. Miscarriage Associated with Zika Virus Infection
  226. Virus genomes reveal the factors that spread and sustained the West African Ebola epidemic.
  227. Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization
  228. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
  229. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
  230. Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015
  231. A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels
  232. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection
  233. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
  234. Cross host transmission in the emergence of MERS coronavirus
  235. Mers Coronavirus Infection in Dromedary Camels
  236. Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone
  237. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia
  238. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
  239. Intrathecal CD4+and CD8+T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients
  240. Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015
  241. Deployment of Dutch mobile laboratories in the West African Ebola virus response
  242. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus–Infected Returning Travelers, the Netherlands, 2014
  243. Novel in vivo and in vitro models of Hepatitis E virus genotype 3 infectivity for chronic human HEV infection
  244. Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014
  245. Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009–2013
  246. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits
  247. Reliable typing of MERS-CoV variants with a small genome fragment
  248. Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct
  249. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells
  250. Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand
  251. Identification of Protein Receptors for Coronaviruses by Mass Spectrometry
  252. Mers coronavirus infection of rabbits
  253. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
  254. Pathogenesis of Middle East respiratory syndrome coronavirus
  255. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
  256. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner
  257. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014
  258. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
  259. Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units
  260. Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses
  261. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  262. Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014
  263. Novel divergent nidovirus in a python with pneumonia
  264. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  265. New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands
  266. The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models
  267. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014
  268. Membrane ectopeptidases targeted by human coronaviruses
  269. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014
  270. Neutralizing the MERS Coronavirus Threat
  271. MERS: emergence of a novel human coronavirus
  272. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
  273. Faculty Opinions recommendation of Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
  274. The Novel Human Coronavirus EMC Causes Disease in Macaques but not in Ferrets
  275. Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes
  276. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
  277. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
  278. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients
  279. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
  280. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
  281. Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011
  282. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
  283. Metagenomic Analysis of the Ferret Fecal Viral Flora
  284. Spiking the MERS-coronavirus receptor
  285. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells
  286. Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer
  287. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters
  288. The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
  289. T-Cell Tropism of Simian Varicella Virus during Primary Infection
  290. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment
  291. Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes
  292. Specific serology for emerging human coronaviruses by protein microarray
  293. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands
  294. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
  295. Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross
  296. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
  297. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
  298. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
  299. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines
  300. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
  301. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
  302. Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA
  303. Picobirnaviruses in the Human Respiratory Tract
  304. Novel Hepatitis E Virus in Ferrets, the Netherlands
  305. Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh
  306. Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
  307. Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice
  308. Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces
  309. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
  310. Contents
  311. Enteric Coronavirus in Ferrets, the Netherlands
  312. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
  313. A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus
  314. Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms
  315. Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species
  316. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
  317. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
  318. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
  319. 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION
  320. Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?
  321. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
  322. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics
  323. The Application of Genomics to Emerging Zoonotic Viral Diseases
  324. Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients
  325. Interferon response in murine plasmacytoid dendritic cells after SARS coronavirus infection
  326. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  327. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  328. SARS
  329. Unraveling the complexities of the interferon response during SARS-CoV infection
  330. Virogenomics: the virus–host interaction revisited
  331. 27 Severe SARS coronavirus infection in aged macaques is associated with reduced expression of anti-inflammatory type-1 interferons
  332. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α
  333. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
  334. Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees
  335. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B
  336. Complete genome analysis of hepatitis C virus subtypes 6t and 6u
  337. Severe acute respiratory syndrome (SARS) vaccines
  338. Contributors
  339. Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B
  340. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)
  341. Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B
  342. Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients
  343. Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients
  344. [520] PREDICTION OF SUSTAINED ALT NORMALIZATION BY VIRAL LOAD DURING PEG-IFN ALPHA-2b TREATMENT FOR HBeAg-POSITIVE CHRONIC HEPATITIS B
  345. P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon
  346. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques
  347. The emerging role of ACE2 in physiology and disease
  348. Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-α
  349. Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection
  350. Novel in-vitro and in vivo models
  351. Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions
  352. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
  353. Coronaviruses and their therapy
  354. Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus
  355. Nonhuman Primate Models for SARS
  356. Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C
  357. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
  358. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
  359. Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer
  360. Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses
  361. Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection
  362. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
  363. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- / 
  364. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
  365. 848 Neoadjuvant prostate cancer gene therapy: Clinical and pre-clinical results
  366. 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project)
  367. Pretreatment Intrahepatic CD8 + Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection
  368. SARS virus infection of cats and ferrets
  369. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  370. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  371. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain
  372. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C
  373. Comparative study of different methods to genotype hepatitis C virus type 6 variants
  374. Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C
  375. Molecular epidemiology of gibbon hepatitis B virus transmission
  376. Rat testicular germ & sertoli cells release different types of bioactive TGF-β in vitro
  377. Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant
  378. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin
  379. Long-term HBV kinetics classification during treatment with adefovir dipivoxil
  380. Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy
  381. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
  382. Corrigendum to “A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection” [Vet. Immunol. Immunopathol. 74 (2000) 121–136]
  383. Foreign-body reaction to dermal sheep collagen in interferon-?-receptor knock-out mice
  384. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection
  385. Cytokine mRNAs in liver biopsy samples predict complete virus eradication with interferon-α ribavirin treatment in chronic hepatitis
  386. Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D
  387. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs
  388. Mice Lacking IL-12 Develop Polarized Th1 Cells During Viral Infection
  389. Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony
  390. Neutrophil induced T-cell apoptosis during a viral infection
  391. Neutrophil induced T-cell apoptosis during a viral infection
  392. Virus-induced type-1 cytokine response in IL-12 deficient mice
  393. Vaccination of pigs with plasmid DNA coding for glycoproteins of pseudorables virus provides protection against challenge infection with pseudorables virus
  394. Transforming growth factor beta production during rat cytomegalovirus infection.
  395. Apoptosis and T-cell depletion during feline infectious peritonitis.
  396. Tumour necrosis factor-  production during cytomegalovirus infection in immunosuppressed rats
  397. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  398. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  399. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.
  400. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.
  401. Tumor necrosis factor α levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection
  402. Pneumococcal conjugate vaccines
  403. Tumour necrosis factor- , interferon-  and interferon-beta exert antiviral activity in nervous tissue cells
  404. Protection of Rats against Pseudorabies Virus Infection by  -Interferon